Physician profile
Mark D Clark
NPI 1205989605
$574.88
in general payments reported to CMS, 2019-2025
13 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $212 · 2020: $50.28 · 2022: $96.88 · 2023: $14.94 · 2024: $81.81 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $215.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $119.17 | 2019-2025 | Sublocade |
| Pear Therapeutics (US), INC. | $75.88 | 2022 | |
| Boston Scientific Corporation | $62.37 | 2019 | |
| Braeburn INC. | $60.99 | 2023-2025 | Brixadi |
| Abbott Laboratories | $55.21 | 2019-2024 | Proclaim |
| Abbvie INC. | $46.47 | 2024-2025 | |
| Nevro Corp. | $32.46 | 2019 | |
| Vanda Pharmaceuticals INC. | $27.35 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $21.45 | 2025 | |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Alkermes, INC. | $18.89 | 2019 | |
| Exact Sciences Corporation | $17.27 | 2025 | Cologuard Collection Kit |
| Uswm, LLC | $16.37 | 2024 | Lucemyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.